Worldwide, more than one million people die each year from hepatitis C virus (HCV) related
diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt …

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …

The occurrence of hepatocellular carcinoma (HCC) is one of the most serious complications
of hepatitis C virus (HCV) infection. Recently, effective antiviral medications have made …

Although studies suggest decreased incident hepatocellular carcinoma (HCC) after
treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are …

Chronic hepatitis C virus (HCV) infection is the principal etiology of cirrhosis and, ultimately,
hepatocellular carcinoma (HCC). At present, approximately 71 million people are chronically …

Hepatitis C virus clearance is expected in more than 95% of patients treated with direct-
acting antivirals (DAAs). However, an extensive debate about the impact of DAAs on the …

Introduction Recent studies have suggested a higher recurrence rate of hepatocellular
carcinoma (HCC) in patients with a history of HCC and hepatitis C virus (HCV)-associated …

The risk of hepatocellular carcinoma recurrence is universal regardless of the treatment
modality applied, and secondary prevention is still an unmet issue even though the …

The treatment for hepatocellular carcinoma (HCC) relies on liver resection, which is,
however, burdened by a high rate of recurrence after surgery, up to 60% at 5 years. No pre …

Background and Objectives: The impact of direct-acting antiviral (DAA)-based regimens on
the recurrence of hepatocellular carcinoma (HCC) after successful curative hepatectomy is …